Assembly Biosciences (ASMB) Cash from Operations (2010 - 2026)

Assembly Biosciences' Cash from Operations history runs 17 years deep, the most recent figure standing at 22097000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 5.73% year-over-year to 22097000.0 in Q1 2026; TTM through Mar 2026 was 39751000.0, a 29.26% increase from a year earlier, with the FY2025 full-year figure at 41093000.0, up 19.61% from the prior year.
• Cash from Operations fell to 22097000.0 in Q1 2026 per ASMB's latest filing, from 14237000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 73647000.0 in Q4 2023 and bottomed at 27502000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 17102000.0 (2024), against an average of 10354529.41.
• Across the five-year window, Cash from Operations sank 100.55% in 2024 and jumped 3598.03% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 19254000.0 in 2022, then surged by 482.5% to 73647000.0 in 2023, then slumped by 100.55% to 407000.0 in 2024, then soared by 3598.03% to 14237000.0 in 2025, then plunged by 255.21% to 22097000.0 in 2026.
• Per Business Quant, the three latest ASMB Cash from Operations figures stand at 22097000.0 (Q1 2026), 14237000.0 (Q4 2025), and 15133000.0 (Q3 2025).